Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ClaSPd: Selinexor combination in relapsed/refractory multiple myeloma
NCT04843579Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Started Dec 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04843579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843579.